首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis.
【24h】

Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis.

机译:合成的α(2)-antiplasmin的羧基末端肽对尿激酶诱导的纤溶作用的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

alpha(2)-Antiplasmin (alpha(2)AP) interferes with the binding of plasminogen to fibrin because lysine residues in its carboxy-terminal region compete with those in fibrin, presumably the same way that free lysine or varepsilon-aminocaproic acid (EACA) inhibits plasminogen binding to fibrin. While this overall process causes an inhibition of fibrinolysis, the converse was observed with a 26-residue synthetic peptide (AP26) corresponding to the carboxy-terminal region of alpha(2)AP. The AP26 peptide, in fact, accelerated urokinase-induced lysis of (1) fully crosslinked fibrin with complete gamma-dimer and alpha-polymer formation; (2) partially crosslinked fibrin that had undergone only gamma-dimerization; and (3) noncrosslinked fibrin. The AP26 peptide also inhibited factor XIIIa-catalyzed crosslinking of fibrin alpha-chains, and this also accelerated lysis of fibrin. EACA had no effect. In the presence of noncrosslinked fibrin, AP26 promoted plasminogen activation by urokinase and fibrinolysis. EACA only slightly increased the rate of plasminogen activation, and as expected, it inhibited fibrinolysis. Since AP26 peptide enhanced the lysis of partially crosslinked and noncrosslinked fibrin, our results indicate that inhibition of factor XIIIa-catalyzed alpha-polymer formation by AP26, although associated with accelerated fibrinolysis, is not the primary mechanism. Instead, our data support the conclusion that AP26 enhances the conversion of plasminogen to plasmin approximately 5-fold, probably by inducing a conformational change in plasminogen structure just as occurs with low concentrations of lysine or EACA. At higher concentrations, however, AP26 apparently does not approach the avidity or affinity of lysine or EACA for the kringle structures of plasminogen or plasmin so that their binding to fibrin is blocked. Whether AP26 alone, or as part of another molecule, could have potential for enhancing thrombolysis will require further study.
机译:alpha(2)-Antiplasmin(alpha(2)AP)干扰纤溶酶原与血纤蛋白的结合,因为其羧基末端区域中的赖氨酸残基与血纤蛋白中的残基竞争,大概与游离赖氨酸或缬草酸-氨基己酸(EACA)相同)抑制纤溶酶原与纤维蛋白结合。虽然此总体过程导致纤维蛋白溶解的抑制,但观察到相反的26残基合成肽(AP26)对应于alpha(2)AP的羧基末端区域。实际上,AP26肽加速了尿激酶诱导的(1)完全交联的血纤蛋白的溶解,具有完整的γ-二聚体和α-聚合物形成; (2)仅发生γ-二聚化的部分交联的纤维蛋白; (3)非交联的纤维蛋白。 AP26肽还抑制因子XIIIa催化的血纤蛋白α链交联,这也加速了血纤蛋白的裂解。 EACA无效。在未交联的纤维蛋白存在下,AP26通过尿激酶和纤维蛋白溶解促进纤溶酶原激活。 EACA仅稍微增加了纤溶酶原激活的速率,并且正如预期的那样,它抑制了纤维蛋白溶解。由于AP26肽增强了部分交联和非交联的血纤蛋白的裂解,因此我们的结果表明,尽管与加速的血纤蛋白溶解相关,但AP26抑制因子XIIIa催化的α-聚合物形成不是主要机制。相反,我们的数据支持以下结论:AP26可以通过诱导纤溶酶原结构的构象变化(与低浓度的赖氨酸或EACA一样)而将纤溶酶原向纤溶酶的转化提高约5倍。但是,在较高浓度下,AP26显然不能达到赖氨酸或EACA对纤溶酶原或纤溶酶的环结构的亲和力或亲和力,因此它们与纤维蛋白的结合被阻断。单独使用AP26还是作为其他分子的一部分,是否可能具有增强溶栓的潜力,尚需进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号